Prescription Drugs

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

• Study Reliability and Reporting Limitations
• Disclaimers
• Data Interpretation & Reporting Level
• Quantitative Techniques & Analytics
• Product Definition and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW & OUTLOOK

• Pharma Industry Hit by Economic Downturn
• Table 1: Worldwide Prescription Drugs Sales: 2006-2015 (includes corresponding Graph/Chart)
• The Regional Impact
• Emerging Markets to Drive Growth
• Biotechnology
• Biotech Bankruptcies Rife in the Current Economic Downturn
• Economic Downturn Takes Toll on R&D
• Outsourcing - A Mixed Bag
• Generics - The Bright Spot
• Table 2: Increasing Share of Generics in the Global Pharmaceutical Market: 1995-2005 (In %) (includes corresponding Graph/Chart)
• Table 3: Generics Share in Select Markets Worldwide - United States, Germany, UK, Spain, Japan, Italy, France, Finland, Denmark, The Netherlands, Norway, and Ireland (includes corresponding Graph/Chart)
• Patent Expiries of Major Drugs: 2009-2012
• Patient Spending
• Operational Restructuring
• Rising R&D Costs Call for Improved Efficiency
• Concerns Over Drug Safety and Side Effects Impede Sales
• Policy Issues Threaten Innovation
• Regulatory Glitches and High Costs Hinder Biogeneric Growth
• Opportunities Outside Drug Development
• Going Forward in Forward Integration
• Forward Integration into Diagnostics
• Opportunities in Healthcare
• Down the Distribution Chain

2. LEADING PHARMA COMPANIES AND DRUGS

• Pfizer Reigns Supreme...
• Table 4: Leading Global Pharmaceutical Companies Worldwide by Sales (2008, 2007, and 2006) - Pfizer, GlaxoSmithKline, Novartis, Sanofi-Aventis, AstraZeneca, Roche, Johnson & Johnson, Merck & Co., Abbott and Eli Lilly - in US$ Billion (includes corresponding Graph/Chart)
• Leading Prescription Drugs Worldwide - Lipitor Leads the Way
• Table 5: Leading Prescription Drugs Worldwide by Sales (2008, 2007, and 2006)- Lipitor, Plavix, Nexium, Seretide, Enbrel, Seroquel, Zyprexa, Remicade, Singulair and Levonox in US$ Billion (includes corresponding Graph/Chart)
• Oncology Tops Therapeutic Classes
• Table 6: Leading Therapeutic Classes Worldwide by Sales (2008, 2007, and 2006)- Oncologics, Lipid Regulators, Respiratory Agents, Proton Pump Inhibitors, Antidiabetics, Antipsychotics, Antidepressants, Angiotensin II Antagonists, Anti-Epileptics, Autoimmune Agents and Others in US$ Billion (includes corresponding Graph/Chart)

3. THERAPEUTIC DRUG CLASSES

• Cholesterol Reducers
• Statins Lead the Way
• Emerging Leaders
• Table 7: Leading Cholesterol Reducing Drugs Worldwide: Sales for the years 2004 through 2008 for Lipitor, Crestor and Vytorin (in US$ Billion) (includes corresponding Graph/Chart)
• Lack of Product Differentiation Mars Prospects
• Zocor - The First Statin to Switch to OTC
• Patent Expiries of Leading Cholesterol Reducers: 2009 and Beyond
• Oncologics
• Oncologics/ Cancer Drugs - Largest Therapeutic Class
• High Unmet Needs to Drive Growth
• Biologics to Reign Supreme
• Leading Drugs
• Leading Players
• Novel Therapies
• Respiratory Drugs
• Leading Brands and Players
• Table 8: Leading Asthma Drugs Worldwide - Value Sales for the Years 2004-2008 for Seretide, Singulair, Symbicort and Pulmicort (in US$ Billion) (includes corresponding Graph/Chart)
• Table 9: Select COPD and Allergic Rhinitis Drugs Worldwide: Value Sales for the Years 2006-2008 for Spiriva, Nasonex and Zyrtec (In US$ Billion) (includes corresponding Graph/Chart)
• Patent Expiries of Leading Respiratory Drugs: 2008 and Beyond
• Antipsychotics
• Leading Schizophrenia Drugs
• Side Effects of Antipsychotics - A Major Issue
• Patent Expiries
• Patent Expiries of Leading Anti-Psychotic Drugs
• Zyprexa Continues to Lose Market Share
• Risperdal Sales to Plunge, Following its Patent Expiry
• Generics - Yet to Make a Mark in Antipsychotics
• Increasing Use of Antipsychotics in Children Raises Concerns
• Proton Pump Inhibitors
• Patent Expiries of Leading Proton Pump Inhibitors: 2008 and Beyond
• Table 10: Leading Proton Pump Inhibitors Worldwide - Value Sales for the Years 2004 through 2006 (US$ Billion) - Nexium, Prevacid/Takepron, Protronix/Pantazol and AcipHex/Pariet (includes corresponding Graph/Chart)
• Antidepressants
• Patent Expiries of Leading Antidepressant Drugs Worldwide: 2005-2015
• Erythropoietins
• Competitive Landscape in the Global Erythropoietin Market
• Leading Erythropoietin Drugs
• Table 11: Leading Erythropoietin Drugs Worldwide - Annual Revenues for the Years 2004 through 2007 in US$ Billion for Aranesp, Procrit/Eprex, Epogen and NeoRecormon (includes corresponding Graph/Chart)
• New and Pipeline Products
• Biogenerics Pose Imminent Threat
• Anti-Arthritics
• Table 12: Leading Anti-arthritic Drugs Worldwide - Value Sales for Years 2006 through 2008 in US$ Billion - Enbrel, Remicade, Rituxan and Humira (includes corresponding Graph/Chart)
• Anti-Epileptics
• Disease Statistics
• Available Drugs
• Generics to Take the Lead in Anti-Epileptic Market
• Table 13: Leading Anti-Epileptic Drugs Worldwide: Value Sales for years 2005 through 2007 in US$ Billion for Topamax, Lamictal, Depakote and Keppra (includes corresponding Graph/Chart)
• Patent Expiries of Leading Anti-Epileptic Drugs
• New Launches
• Pipeline Drugs Bode Brighter Prospects
• Pipeline Drugs in Antiepileptics
• Calcium Channel Blockers
• Antidiabetics
• Table 14: Leading Anti-diabetic Drug Sales Worldwide: Value Sales for Years 2005 through 2008 in US$ Billion for Actos, Lantus, Avandia Franchise, Januivia and Byetta (includes corresponding Graph/Chart)

4. MARKET DYNAMICS

• Pharma M&A Activity in 2008
• Aggressive M&A Deals by Japanese Companies
• Patent Expiries
• Patent Expiries for 2008 and 2007
• New Product Approvals
• Table 15: New Drugs Approval from 2003-2008 (includes corresponding Graph/Chart)
• Table 16: Biologics Approvals from 2003-2008 (includes corresponding Graph/Chart)
• Table 17: Development of New Molecular Entities (Biological and Chemical) by Various Region/Country: Percentage Share Breakdown for the Periods 1998-2002 & 2003-2007 (includes corresponding Graph/Chart)
• Table 18: Number of Compounds Under Development by Country/Region: Percentage Breakdown for the year 2007 (includes corresponding Graph/Chart)
• New Molecular Entities (NMEs) Approved by FDA in 2008
• New Biological Entities Approved by FDA in 2008
• Research and Development
• Table 19: R&D Investments by Pharmaceutical Sector in US and Europe: 2004-2007 (includes corresponding Graph/Chart)
• Cost Pressures
• R&D Productivity Slides Despite Increasing Investments
• Aging Population Drives Demand
• Table 20: World Demographic Trends: People Over 65 as a Percentage of Total Population by Geographic Region- US, Canada, Japan, Europe, Asia-Pacific, and Latin America for years 2000, 2008, 2010, and 2020 (includes corresponding Graph/Chart)

5. PRESCRIPTION PHARMACEUTICALS -

• Biologics
• Evolution Of The Global Pharmaceutical Industry
• Drug Development Process - FDA Perspective
• Stages of Drug Development Process
• Drug Discovery
• Pre-Clinical Testing
• Clinical Trials
• Phase I Clinical Trial
• Phase II Clinical Trial
• Phase III Clinical Trial
• New Drug Application
• FDA Review
• Phase IV Clinical Trials
• FDA' s Drug Safety Review - The Global Standard

6. SELECT THERAPEUTIC CLASSES

• Anti-arthritics
• COX-2 Inhibitors
• Antipsychotic Drugs
• Anti-Ulcerants
• Codeine & Combinations
• Combination Drugs
• Anti-Depressants
• Selective Serotonin Reuptake Inhibitors (SSRIs)
• Serotonin Noradrenaline Re-Uptake Inhibitors (SNRIs)
• Serotonin Modulators (5-HT2 blockers)
• Dopamine-norepinephrine Reuptake Inhibitors
• Monoamine Oxidase Inhibitors (MAOIs)
• Erythropoietin
• Proton Pump Inhibitors
• Seizure Disorder Drugs
• Antihistamines
• Calcium Channel Blockers
• Cholesterol Reducers

7. MARKETING AND PROMOTIONS

• Table 21: Promotional Spending by Major Pharma Companies (2006 and 2007) in US$ Million - Pfizer, GlaxoSmithKline, Merck, AstraZeneca, Sanofi-Aventis, Novartis, Eli Lilly, Schering-Plough, Johnson & Johnson, and Bristol Myers Squibb (includes corresponding Graph/Chart)
• Table 22: Promotional Spending through Professional Detailing by Major Pharma Companies (2006 and 2007) in US$ Million - Pfizer, GlaxoSmithKline, Merck, AstraZeneca, Novartis, Sanofi-Aventis, Eli Lilly, Johnson & Johnson, Schering-Plough and Wyeth (includes corresponding Graph/Chart)
• Table 23: Direct-To-Consumer Promotional Spending By Major Pharma Companies (2006 and 2007) in US$ Million - Pfizer, GlaxoSmithKline, Merck, Bristol Myers Squibb, Sepracor, AstraZeneca, Schering-Plough, Sanofi-Aventis, Boehringer Ingelheim and Eli Lilly (includes corresponding Graph/Chart)
• Table 24: E-Promotional Spending by Major Pharma Companies (2006 and 2007) in US$ Million - Merck, GlaxoSmithKline, Johnson & Johnson, Pfizer, Shire, Eli Lilly, Schering-Plough, AstraZeneca and Sanofi- Aventis (includes corresponding Graph/Chart)

8. RECENT INDUSTRY ACTIVITY

• Merck & Co. and Schering-Plough to Merge
• Pfizer to Acquire Wyeth
• CSL and Talecris Biotherapeutics to Withdraw Merger Agreement
• AstraZeneca Partners with Merck to Analyze a New Combination of Anticancer Regimen
• Sun Pharmaceutical Acquires Chattem
• Novartis Acquires 25% Stake in Alcon
• Takeda Acquires Millenium Pharmaceuticals
• Teva Acquires Barr
• Invitrogen and Applied Biosystems Merge
• Eli Lilly Takes Over ImClone Systems
• Daiichi- Sankyo Acquires Controlling Stake in Ranbaxy
• Fresenius Acquires APP Pharmaceuticals
• TPG Acquires 50% Stake in SIA International
• GSK Acquires Sirtris
• Shire Aquires Controlling Interest in Jerini
• Boehringer Ingelheim to Purchase Actimis Pharmaceuticals
• Sanofi Pasteur Acquires Acambis
• Sanofi-Aventis Acquires Symbion
• Nordic and Avista Acquires ConvaTec
• King Pharmaceuticals Acquires Alpharma
• Shionogi Acquires Sciele
• Ranbaxy Inks Indian Marketing License for GLIADEL(r) with BioPro
• Tibotec Gains EC Approval for PREZISTA(r)' s Extended Indication
• GSK and Neptunus to Set up Joint Venture for Developing Flu Vaccines
• AstraZeneca Obtains TRO for Generic Pulmicort Respules
• Solvay Pharmaceuticals Enters Into a License Deal with Depomed
• AstraZeneca Enters into an Agreement with Par Pharmaceutical
• BioReliance and Provecs Enter into Agreement
• Cornerstone BioPharma and Critical Therapeutics Merge to Form Cornerstone Therapeutics
• GSK to Acquire Genelabs
• Lpath and Merck Serono Forge Partnership
• Allergan and Spectrum Ink Collaboration Deal for Bladder Cancer Drug
• EMD Signs Licensing and Collaboration Deal with Theratechnologies
• Medimetriks Receives License for Prescription Brands from Perrigo
• Forest Partners with Phenomix for Developing Diabetic Drug
• GSK Biologicals and AFFiRiS Sign Collaboration Agreement
• Sanofi-Aventis Strengthens R&D Operations in the Chinese Market
• UCB and Pfizer Establish Cyclofluidic
• Valeant Pharmaceuticals Completes Coria Laboratories Acquisition
• MedImmune Inks Agreement with Omninvest over Reverse Genetic Technology
• Avidas Secures North American Rights of Crown' s Dermatology Products
• Lilly Acquires Two Compounds for Early-Stage Tuberculosis Drug Pipeline
• Eli Lilly and Deciphera Enter into Collaboration and Licensing Deal
• Roche, GlycArt and Genentech Sign Collaboration Agreement
• Cardinal Health Plans to Spin-Off Medical and Clinical Products Businesses
• Sanofi Pasteur Holding Acquires Acambis
• Eisai Plans NDA Submission for Insomnia Drug
• GlaxoSmithKline Enter into Strategic Alliance with Cellzome
• Ablynx and Merck Serono Sign Nanobodies(r) Agreement
• GlaxoSmithKline and Valeant Enter into Collaborative Agreement
• Noven Enters Supply and License Agreements with P&G Pharmaceuticals
• Eli Lilly Acquires SGX Pharmaceuticals
• SymBio Pharmaceuticals Enters into a License Agreement with Eisai
• Roche Sells Four Pharmaceutical Products to Meda AB
• AstraZeneca Joins Hands with Abbott for Co-Promotion of Crestor
• Gilead Sciences Inks Atripla(r), HIV Drug Distribution Deal with Merck
• Eisai China Enters into Licensing Deal with Health Vision
• GSK and Harvard Stem Cell Institute Team Up for Drug Discovery
• Teva Acquires Bentley Pharmaceuticals
• Roche to Acquire ARIUS Research
• GlaxoSmithKline and Actelion Collaborate
• GSK Enters into Product Disinvestment Agreement with Aspen
• Lupin Forges Marketing Alliance with ASCEND for Suprax(r) Tablets
• Merck Serono Inks Multiple Sclerosis Drug-Development Deal with Bionomics
• European Commission Approves Kuvan(r) of Merck Serono
• GSK Collaborates with Mpex for Developing Anti-Bacterial Drugs
• Eli Lilly Announces Development & Licensing Agreement with TransPharma
• Mylan Obtains Exclusive Marketing Rights for Glatiramer from NATCO
• Sepracor Acquires Oryx Pharmaceuticals
• Mylan Takes Over Merck' s Outstanding Generics Operations
• Gilead Acquires Cicletanine Business from Navitas
• King Pharmaceuticals to License Third Opioid Analgesic Product
• BioPhausia Acquires Prescription Pharmaceutical Offerings from AstraZeneca
• Ranbaxy Enters into Strategic Product Development Agreement with Merck
• EUSA Pharma Acquires Cytogen Corporation
• Dr. Reddy' s Announces Two Major Acquisitions
• EUSA Divests Stake in Antibody Research and Oncology Product to IDD
• Sanofi Pasteur Delivers H5N1 Bulk Vaccine Antigen to HHS
• Ranbaxy Inks Strategic Business Alliance with Orchid
• Pfizer Settles Patent Litigation for Lipitor with Ranbaxy
• GSK Enters into Collaboration with Regulus Therapeutics
• Janssen to Launch J&J Group' s New Drugs in Japan
• Roche Alliance Partner Obtains Approval for Actemra in Japan
• Abbott Receives Japanese Approval for Rheumatoid Arthritis Drug, HUMIRA(r)
• Dr. Reddy' s Completes Acquisition of Jet Generici Srl
• Eli Lilly, Transition Therapeutics Announce Licensing and Partnership Agreement
• Dr. Reddy' s and 7TM Sign Drug Discovery Agreement for Selected Drug Targets
• Endo Pharmaceuticals Obtains US Rights for Novartis' Voltaren(r) Gel
• Pfizer to Take Over Serenex
• Sanofi-aventis, Amyris, iOWH Sign Semisynthetic Artemisinin Development Deal
• AstraZeneca Files sNDA for Depressive Disorder Drug, Seroquel XR(tm)
• Forest, Mylan Amend Bystolic Agreement
• Fujifilm to Acquire Stake in Toyama Chemicals
• Graceway Takes Over Estrasorb
• Ranbaxy Announces De-Merger of New-Drug Discovery Research Unit
• AstraZeneca Inks Deal with Nomura Phase4 Ventures to Form Albireo
• Cellegy to Merge with Adamis Pharmaceuticals
• Mylan Reaches Accord with Novartis for Femara(r)' s Generic Product
• Dyax Signs Licensing and Development Agreements with Sanofi-aventis
• AstraZeneca Files for EU Approval of Seroquel XR(tm)
• MedImmune Files Biologics License Application for motavizumab to FDA
• Farmavita, Belupo Sign Contract for Strategic Merger
• Pfizer Japan Secures Production and Marketing Approval for Champix(r)
• Eisai Enters into License Agreement with Abbott
• Eisai Takes Over MGI Pharma
• KV Pharmaceutical to Acquire Rights for Gestiva(tm) from Hologic
• Forest and Novexel Enter into Licensing Agreement
• Dr. Reddy' s Enters Settlement Agreement with Novartis for Exelon(r)
• Taisho and Pfizer Sign Agreement for TS-032
• Crucell Enters into Agreement with Sanofi Pasteur
• EMEA Approves Second Biogeneric EPO, Retacrit
• Endo Pharmaceuticals Licenses AZ-003 from Alexza
• Schering-Plough and Centocor Modify Existing Distribution Agreement
• GSK and Santaris Pharma Collaborate in RNA Antagonists Research
• GSK Acquires Reliant Pharmaceuticals
• Eisai and Minophagen Ink In-Licensing Agreement for Liver Disease/ Allergic Disease Agents
• Bristol-Myers, Gilead Extend Agreement to Commercialize ATRIPLA(r) in Europe
• GSK and OncoMed Team Up for Antibody Therapeutics for Cancer Stem Cell Research
• GSK Allies with Galapagos for Antiviral and Antibacterial Development
• Eisai and BioArctic Ink Licensing Deal for BAN2401
• Biogen and Neurimmune Join Hands to Develop Drugs for Alzheimer' s Disease
• Sanofi-aventis Institutes GDC, Pharmaceutical Development Center in India
• AstraZeneca Obtains Pediatric Exclusivity for ARIMIDEX(r) from FDA
• Covance to Build High-Tech Drug Development Facility
• Schering-Plough Takes Over Organon BioSciences
• Takeda Launches Takeda San Francisco for Therapeutic Antibody Research
• GSK to Disinvest Lotronex(r)
• Gilead and LGLS Enter Global License Deal for Fibrotic Diseases Therapy
• Watson Acquires Andrx
• EPFL and Merck Serono Enter into Agreement
• Acura and King R&D Sign Licensing Agreement for Opioid Analgesic Products
• Eli Lilly Inks License Agreement with Glenmark Pharmaceuticals
• Wockhardt Takes Over Morton Grove Pharmaceuticals
• GSK Enters into Collaboration with Tolerx for Development of Novel Therapies
• Chugai Pharmaceuticals Obtains Approval for Tarceva in Japan
• Eli Lilly Announces Strategic Alliance with MacroGenics
• BMS, ImClone, Merck Serono Sign Erbitux(r) Agreement
• Wockhardt to Market Gnosis' SAMe in India
• Alpharma Grants US License for Ketoprofen in Transfersome(r) Gel to IDEA
• Forest and Daiichi Sankyo Sign Contract to Co-Promote AZOR(tm)
• Synta and GSK Sign Oncology Molecule Development Collaboration
• Cyclacel to Take Over ALIGN Pharmaceuticals and ALIGN Holdings
• GSK Inks Antiviral and Antibacterial Drug Development Deal with Anacor
• AMRI Enters into Research Collaboration with Cystic Fibrosis Foundation
• Mylan Takes over Merck Generics
• Kissei and Eisai Ink Licensing Deal for Glufast(r) Tablets
• AMRI Inaugurates New Research Unit in Hyderabad
• Eisai Inks Co-Promotion Deal with Salix for COLAZAL(r) Capsules
• Kowa and Teva to Establish Joint Venture Generic Drug Firm in Japan
• Nisshin Seifun Pulls Out of Joint Venture Nisshin Kyorin Pharmaceutical
• Chugai and Teijin Sign Agreement for Co-Development of Anti-Diabetic Drug
• MedImmune Inks Licensing Agreement with Novartis over Reverse Genetic Technology
• EUSA Acquires Assets of Innocoll
• Noven Enters Supply and License Agreements with P&G Pharmaceuticals
• Parion and Gilead Ink Deal to Develop Drug Candidates for Pulmonary Disease
• Noven Pharmaceuticals Acquires JDS Pharmaceuticals
• HHS Places an Order with GSK for Bulk H5N1 Antigen
• Synthon Completes Laboratorios Rider Acquisition
• Targacept Forges Partnership with GSK
• Dong Wha Signs Alliance with P&G Pharma to Develop Treatment Molecules for Osteoporosis
• Barr and Gedeon Richter Sign Pact over Generic Version of LAMISIL(r)
• Santarus and Victory Pharma Enter Into Co-Promotion Agreement
• AMRI Enters into Collaboration for Research with Achaogen
• SCI Collaborates with High Q Foundation for Research on Huntington' s Disease
• MonoSol Rx Signs License Agreement with Strativa Pharmaceuticals
• Eli Lilly to Launch Public-Private Partnership for Drug Research in Tuberculosis
• Merck Serono and Bristol-Myers Squibb Ink Latin American Distribution Deal
• Strides Arcolab to Take Over Bio-Fermentation Facility in Italy
• Amgen to Take Over Alantos Pharmaceuticals
• GlaxoSmithKline Establishes R&D Center in China
• Wockhardt Acquires Negma Laboratories
• Eisai Inks Exclusive Agreement with Solstice over NeuroBloc(r)
• Ranbaxy to Acquire Be-Tabs Pharmaceuticals
• Pfizer Obtains Health Canada Approval for LIPITOR in Reducing Myocardial Infarction
• GSK Allies with Wellcome to Develop Antibacterials for Hospital-Contracted Infections
• Bristol-Myers and Pfizer Ink Development and Commercialization Agreements
• Cytos Biotechnology Grants Novartis with Global License for NicQb
• Swiss Federal Register Adds ACOMPLIA(r) to Reimbursement List
• Wockhardt to Introduce Syrio Pharma' s B-Lift Product Range in India
• Eisai Acquires Morphotex
• Ranbaxy Obtains Approval for RAN(tm) Cefprozil Formulations in Canada
• Roche Partners with Transgene to Focus on Therapeutic Vaccine Program
• Cardinal Health Divests Pharmaceutical Technologies and Services Segment to Blackstone Group
• Roche to Acquire BioVeris Corporation
• Eli Lilly Acquires Hypnion
• Roche Takes Over THP, Broadens Antibody Research Facility
• Oxford BioMedica Enters into Development Deal with Sanofi-Aventis for TroVax(r)
• Iroko Pharmaceuticals Acquires Rights to Indocin(r) and Aldomet(r) Products
• Asahi Kasei Inks Licensing Agreement with Eisai Korea over Vasodilator Eril(r)
• Merck Obtains EU Approval for JANUVIA(tm) Type 2 Diabetes Drug
• Wockhardt Obtains FDA Approval for a Painkiller in the US
• Ortho-McNeil Obtains Pediatric Extension for LEVAQUIN(r)
• GlaxoSmithKline Obtains FDA Approval for Tykerb(r)
• Terapia Ranbaxy Secures Marketing Approvals for 20 New Products
• Shionogi to Develop and Market BioCryst' s peramivir in Japan
• Abbott and Eisai Amend Co-Promotion Agreement over HUMIRA(r) in Korea and Taiwan
• Salix Acquires US Rights to Merck' s Two Oral Suspension Products
• Takeda Expands Collaboration with XOMA in Potential Therapeutic Antibody Programs
• GSK Commences Phase III Clinical Trials of Tykerb(r), a Post-Operative Lapatinib
• Roche Grants Glaxo with Exclusive Licensing Rights to its ' Orlistat' Drug
• GSK and HGS Commence Phase III Trials of LymphoStat-B(r) in SLE
• GSK and Fabre-Kramer Ink Global Deal for Gepirone ER
• Ranbaxy Signs Agreement with Zenotech for Biosimilars' Global Launch
• Ranbaxy Inks Long-Term R&D Deal with GSK
• Amgen Inks Three-year Aranesp Supply Agreement with Fresenius
• AstraZeneca to Take Over Arrow Therapeutics
• Eli Lilly Acquires ICOS Corporation
• Pfizer Plans to Takeover BioRexis
• Solvay Inks Licensing Deal with Jazz Pharmaceuticals for LUVOX(r)
• Eisai' s ' Pariet(r), 10mg Tablets' Receive Clearance for New Indication in Japan
• Eisai Receives EC Approval for Inovelon(r)
• Pfizer Receives Marketing Authorization for Sutent(r) in European Union
• GlaxoSmithKline Obtains Approval to Market Wellbutrin XR(r) in the Netherlands
• Forest Laboratories Acquires US Biopharmaceutical Company, Cerexa
• Mylan Laboratories Acquires 51.5% in Matrix
• DUSA Enters into an Agreement with Daewoong Pharmaceutical
• Penwest and Endo Amend Existing Contract on Opana(r) ER Collaboration
• Eli Lilly Licenses Glucokinase Activator Program from OSI Pharmaceuticals
• Graceway Pharmaceuticals Acquires 3M Pharmaceuticals Business
• Ranbaxy Obtains FDA Approval for Atenolol Tablets
• Gilead Sciences Acquires Myogen
• Gilead Sciences Acquires Raylo Chemicals

9. FDA APPROVALS FOR 2009, 2008 AND 2007

10. A REVIEW OF SELECT PRODUCT

• Amgen Receives Approval for Nplate(R)...
• Takeda Wins FDA Marketing Approval for ULORIC...
• Novartis and MMV Launch Coartem(r) Dispersible
• Ipsen and Medicis Receives FDA Approval for Dysport...
• Centocor Receives FDA Approval for Simponi...
• Wyeth Receives FDA Approval for PRISTIQ(tm)...
• GSK Receives FDA Approval for Promacta(r)...
• Cephalon Receives FDA Approval for TREANDA...
• Adolor Receives FDA Approval For Entereg(R)...
• Lundbeck Introduces Xenazine* (Tetrabenazine) Tablets
• Eisai US Receives FDA Approval for Banzel(tm) (Rufinamide)
• Progenics Receives FDA Approval for RELISTOR...
• J&J Receives Approval for Anti-HIV Medication ' Intelence' ...
• Sandoz Launches Generic Fluoxetine Hydrochloride Capsules in US
• Sandoz Introduces Eplerenone Tablets
• Wockhardt Introduces Midazolam Injection in the US
• Dr. Reddy' s Announces Launch of Generic Version of Imitrex(r) Tablets
• Arbor Pharmaceuticals Debuts NEOTIC(tm) for Middle- Ear Infections
• Promius Pharma Introduces EpiCeram(r) Emulsion
• Sandoz Unveils Generic Variant of Imitrex(r) Injection
• Dr. Reddy' s Launches Redihaler(tm) and Combihale(tm)
• Wyeth Launches Antihemophilic Factor, XYNTHA(tm)
• Bayer Schering Releases YAZ(r)
• Mylan Introduces Nisoldipine ER Tablets in US
• Ranbaxy Launches Generic Omeprazole in US
• Ranbaxy Unveils Generic Equivalent of Amlodipine Tablets
• Teva Unveils Generic Equivalent of Lamictal(r) Tablets
• Eisai and Helsinn Healthcare Introduce ALOXI(r) Injection for Prevention of PONV
• Janssen and Patriot Unveil Authorized Generic Equivalent for Risperdal(r)
• Watson Releases Generic Equivalent of MARINOL(r)
• Sandoz Introduces Generic Form of Altace(r)
• Abbott Introduces Aluvia(r) Tablet in South Africa
• Dr. Reddy' s Rolls-out Atocor-R
• Sandoz Unveils Generic Form of Maxipime(r)
• Tibotec Therapeutics Introduces New 600mg Dosage Strength for PREZISTA
• Ranbaxy Pioneers Launch of New Bio-Generic Recombinant Osteoporosis Injection
• Sandoz Introduces Generic Variant of Antizol(r) Injection
• Sun Pharmaceuticals Introduces Injection of Amifostine
• Sandoz Re-Launches Generic Form of Bactocill(r) Injection
• Sandoz Introduces Generic Form of Cipro(r) Injection
• Merck Serono Introduces Cyanokit(r) in Japanese Market
• Ranbaxy Launches INERSAN Tablets in India and Nepal
• Sandoz Launches Omnitrope(tm) Pen 5 with Liquid Cartridge
• Endo Pharmaceuticals to Introduce OPANA(r) ER in Three Dosage Strengths
• Sandoz Releases Generic Form of Camptosar(r)
• Sun Pharmaceuticals Unveils Pantoprazole Sodium DR Tablets
• Dr. Reddy' s Introduces Supanac(r)
• Watson Announces Launch of Clarithromycin 500mg Extended-Release Tablets
• GSK Announces FDA approval of Altabax(tm)...
• Novartis' Tekturna HCT(r) Receives FDA Approval...
• GSK Receives FDA Approval for Tykerb(r)...
• Pfizer Receives FDA Approval for Selzentr...
• Ortho-McNeil Receives Approval for DORIBAX(tm)...
• Merck Receives Approval for Isentress(r) ...
• BMS Wins FDA Approval for IXEMPRA(tm)...
• Novartis' Tasigna(r) Receives FDA Approval...
• Mylan Receives FDA Approval for Bystolic...
• Roche' s Mircera Secures FDA Approval...
• Eisai Launches New Dose Formulations of Aricept(r) Tablets in Japan
• Chugai Launches Tarceva(r) Tablet in Japan
• Sandoz Introduces Generic Version of Elocon(r) Lotion
• Ranbaxy to Introduce Tamsulosin Hydrochloride Capsules in Canada
• Watson Unveils Tilia(tm) Fe
• Ranbaxy Obtains Health Canada Approval for Ran(r)- Lisinopril Oral Tablets
• Sandoz Releases Generic Form of Delestrogen(r) Injections
• Sanofi and UCB Roll Out XYZAL(r) in US
• Sandoz Expands Range of Generic Augmentin(r) Drugs
• Sandoz Releases Generic Variant of Biaxin(r) for Oral Suspension
• Sandoz Introduces Generic Form of Penlac(r) Topical Solution
• Teva Releases Famciclovir Tablets
• Ranbaxy Introduces Roliflo OD in India
• Sandoz Introduces Generic Form of Toprol Xl(r) 50Mg Extended Release Tablet
• Dr. Reddy' s Introduces Glimy MP1 and Glimy MP2
• Sandoz Launches Approved Generic Equivalent of Lamisil(r)
• Ranbaxy Introduces Pravastatin Sodium 80mg Tablets in the US
• AstraZeneca Announces the Availability of Symbicort(r) pMDI
• Chugai and Maruho Announce the Launch of Oxarol(r) Lotion
• Ajinomoto and Eisai Jointly Launch ' Actonel(r) 17.5mg Tablets'
• Sandoz Introduces Approved Generic Form of Lotrel(r)
• Dr. Reddy' s Launches UltravexTM
• Wockhardt Unveils Zolpidem Tablets in the US
• Dr. Reddy' s Introduces Reditux(tm)
• Dr. Reddy' s Secures Approval for Launching Zolpidem Tartrate Tablets
• Cipla Introduces Virenza Inhalation Capsules in India
• Ranbaxy Introduces Osovair in India
• GlaxoSmithKline Introduces Coreg CR(tm)
• Chugai Announces the Launch of Antiviral Agent, Copegus(r) Tablet
• Ranbaxy Unveils Generic Atorvastatin in Denmark
• Barr Unveils Generic ' PROSCAR(r)' Tablets
• Ranbaxy Introduces Niftran 100mg Capsules and Eligard 22.5mg and 45mg
• Barr Releases METAGLIP(tm) Tablets
• SkinMedica Rolls Out Single-Dosage NeoBenz(r) Micro SD for Treating Acne
• Teva Rolls Out Generic Equivalent of Wellbutrin XI(r) Tablets
• Takeda Launches Takepron (r) I.V for Injection 30mg
• Takeda Launches duetact(tm) Combination Drug in USA
• Teijin Pharma Launches Bonalon(r) Tablet for Treating Osteoporosis

11. FOCUS ON SELECT GLOBAL PLAYERS

• Abbott Laboratories (USA)
• Allergan, Inc. (USA)
• Amgen, Inc. (USA)
• AstraZeneca (UK)
• Bayer AG (Germany)
• Bristol-Myers Squibb (USA)
• Boehringer Ingelheim Group (Germany)
• Dr. Reddy' s Laboratories Ltd. (India)
• Eli Lilly and Company (USA)
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Genentech, Inc. (USA)
  • GlaxoSmithKline Plc (UK)
  • Johnson & Johnson, Inc. (USA)
  • Merck & Co. Inc. (USA)
  • Merck Serono International S.A. (Switzerland)
  • Mylan, Inc. (USA)
  • Novartis AG (Switzerland)
  • Pfizer, Inc. (USA)
  • Ranbaxy Laboratories Limited (India)
  • Sanofi-Aventis SA (France)
  • Sanofi Pasteur (France)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Watson Pharmaceuticals, Inc. (USA)
  • Wyeth (USA)

12. GLOBAL MARKET PERSPECTIVE

• Table 25: World Recent Past, Current & Future Analysis for Prescription Drugs Market by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)
• Table 26: World Historic Review for Prescription Drugs Market by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart)
• Table 27: World 15-year Perspective for Prescription Drugs Market by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2003, 2009 & 2015 (includes corresponding Graph/Chart)
• Table 28: World Recent Past, Current & Future Analysis for Prescription Drugs Market by Therapeutic Class - Oncologics, Lipid Regulators, Respiratory Agents, Proton Pump Inhibitors, Antidiabetics, Antipsychotics, Antidepressants, Angiotensin II Antagonists, Anti-Epileptics, Autoimmune Agents and Others Markets Independently Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)
• Table 29: World Historic Review for Prescription Drugs Market by Therapeutic Class - Oncologics, Lipid Regulators, Respiratory Agents, Proton Pump Inhibitors, Antidiabetics, Antipsychotics, Antidepressants, Angiotensin II Antagonists, Anti-Epileptics, Autoimmune Agents and Others Markets Independently Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart)
• Table 30: World 15-year Perspective for Prescription Pharmaceuticals Market by Therapeutic Class- Percentage Breakdown of Dollar Sales for Oncologics, Lipid Regulators, Respiratory Agents, Proton Pump Inhibitors, Antidiabetics, Antipsychotics, Antidepressants, Angiotensin II Antagonists, Anti-Epileptics, Autoimmune Agents and Others Markets for Years 2003, 2009 & 2015 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

• A. Market Analysis
  • Generics in the US
  • Biologics Post Highest Growth
  • Leading Prescription Drugs in the US
  • Table 31: Leading Prescription Drugs in the US by Value Sales (2008) in US$ Billion - Lipitor, Nexium, Plavix, Advair Diskus, Seroquel, Singulair, Enbrel, Neulasta, Actos and Epogen (includes corresponding Graph/Chart)
  • Leading Therapeutic Classes in the US
  • Table 32: US Leading Therapeutic Classes by Revenue (2006-2008): Revenues for Antipsychotics, Lipid Regulators, Proton Pump Inhibitors, Seizure Disorders, Anti-Depressants, Angiotensin II Antagonists, Anteneo Monoclonal Antibodies, Erythropoietins, Anti-Arthritics and Oral Antiplatelets (in US$ Billion) (includes corresponding Graph/Chart)
  • Table 33: US Leading Therapeutic Classes by Dispensed Prescriptions (2006-2008): Percentage Share Breakdown for Lipid Regulators, Codiene & Combinations, Anti- Depressants, Ace Inhibitors, Beta Blockers, Proton Pump Inhibitors, Seizure Disorders, Synthetic Thyroid Hormones, Calcium Blockers, Benzodiazepines, and Others (includes corresponding Graph/Chart)
  • Leading Players
  • Table 34: Leading Companies in the US Pharmaceutical Market (2006-2008): Percentage Breakdown of Value Sales for Pfizer, GlaxoSmithKline, Merck & Co., Johnson & Johnson, AstraZeneca, Amgen, Novartis, Hoffman-La Roche, Sanofi-Aventis, Eli Lilly and Others (includes corresponding Graph/Chart)
  • Table 35: US Pharmaceutical Market (2006-2008): Percentage Breakdown of Dispensed Prescriptions for Teva Pharmaceuticals, Mylan Laboratories, Novartis, Watson Pharma, Pfizer, Barr Laboratories, Merck & Co., Mallinckrodt, Apotex, Qualitest, and Others (includes corresponding Graph/Chart)
  • Prescription Drug Spending
  • Table 36: Healthcare Spending in the US by Sector (2006) (includes corresponding Graph/Chart)
  • Increasing Share of Government in Prescription Drug Spending
  • Table 37: US Prescription Pharmaceutical Industry (2005 and 2006): Percentage Breakdown of Prescription Pharmaceutical Spending by Source for Private Insurance, Medicare, Medicaid, Out-of-Pocket and Other Public Spending (includes corresponding Graph/Chart)
  • Medicare Part D
  • Drug Price Regulations in the US
  • Pharmaceutical Marketing - A High Investment Area in the US
  • Table 38: Pharmaceutical Promotional Spending in the US by Type (2006-2008): Professionals-Directed Promotions and Consumer-Directed Promotions (in US$ Billion) (includes corresponding Graph/Chart)
  • Major Distribution Channels
  • Table 39: Major Prescription Drugs' Distribution Channels in the US by Dispensed Prescriptions (2006-2008): Percentage Share Breakdown for Chain Stores, Independent Stores, Food Stores, Long-term Care, and Mail Order (includes corresponding Graph/Chart)
  • Table 40: Major Prescription Drugs' Distribution Channels in the US by Value Sakes (2006-2008): Percentage Breakdown for Distribution Channel for Chain Stores, Mail Order, Independent Stores, Clinics, Non-government Hospitals, Food Stores and Other Channels (includes corresponding Graph/Chart)
  • Fewer Product Launches
  • Generic Penetration and PBMs Moderate Prescription Drug Price Growth
  • Co-payment Differentials to Increase Generic Substitution
  • High Prescription Drug Costs Drive Drug Re- Importation
  • Direct-to-Consumer Advertising
  • The 2006 Revision of Package Insert Format
  • Other Initiatives
  • Role of PBMs in the Pharmaceutical Supply Chain
  • Prescription Drug Pricing in US
  • Role of Mail-Order Pharmacies in Cost Containment
  • Product Launches
  • Strategic Corporate Developments
  • Select Key Players
• B. Market Analytics
  • Table 41: US Recent Past, Current & Future Analysis for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)
  • Table 42: US Historic Review for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart)
  • Table 43: US Recent Past, Current & Future Analysis for Prescription Pharmaceuticals by Therapeutic Class - Antipsychotics, Lipid Regulators, Proton Pump Inhibitors, Seizure Disorder Drugs, Anti-Depressants, Angiotensin II Antagonists, Antineo Monoclonal Antibodies, Erythropoietins, Others, Market Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)
  • Table 44: US Historic Review for Prescription Pharmaceuticals by Therapeutic Class - Antipsychotics, Lipid Regulators, Proton Pump Inhibitors, Seizure Disorder Drugs, Anti-Depressants, Angiotensin II Antagonists, Antineo Monoclonal Antibodies, Erythropoietins, Others, Market Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart)
  • Table 45: US 15-Year Perspective for Prescription Pharmaceuticals by Therapeutic Class - Percentage Breakdown of Dollar Sales for Antipsychotics, Lipid Regulators, Proton Pump Inhibitors, Seizure Disorder Drugs, Anti-Depressants, Angiotensin II Antagonists, Antineo Monoclonal Antibodies, Erythropoietins, and Others for Years 2003, 2009 & 2015 (includes corresponding Graph/Chart)

2. CANADA

• A. Market Analysis
  • Current and Future Analysis
  • Leading Drugs
  • Table 46: Leading Prescription Drugs in Canada in Terms of Number of Dispensed Prescriptions (2006 and 2007) in Million Scripts: Lipitor, Synthroid, Norvasc, Asaphen, Pantoloc, Crestor, Altace, Ratio- Salbutamol Hfa, Novo-Venlafaxine XR and Apo- Furosemide (includes corresponding Graph/Chart)
  • Major Therapeutic Classes
  • Table 47: Leading Therapeutic Classes in Canada in terms of Dispensed Prescription (2006 and 2007): Percentage Breakdown of Cardiovascular, Antipsychotics, Gastrointestinal/Genitourinary, Lipid Regulators, Hormones, Systemic Anti-infective, Analgesics, Diabetes Therapy, Diuretics, Neurological Disorders and Others (includes corresponding Graph/Chart)
  • Prescription Drugs Spending on the Rise
  • Private Sector Insurance Continues to Gain Popularity
  • Canadian Prescription Drugs Market- A Comparison with the US
  • Generic Sales to Outpace Branded Drugs Sales
  • Generics Market in Canada
  • Generics to Offer Potential Cost Savings
  • New Patented Drugs- Adding Costs but Little Value
  • Two-level Drug Approval Process in Canada
  • Policy Differences Affect Generic Substitution Among Provinces
  • Applied and Other Research Take Major Chunk of R&D Investments in Canada
  • Table 48: Investments in Research & Development in Canada (1998, 2001, 2004 and 2007): Percentage Breakdown by Research Type- Applied Research, Basic Research and Other Research Areas (includes corresponding Graph/Chart)
  • Product Launches
  • Strategic Corporate Developments
• B. Market Analytics
  • Table 49: Canadian Recent Past, Current & Future Analysis for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)
  • Table 50: Canadian Historic Review for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart)

3. JAPAN

• A. Market Analysis
  • Current and Future Analysis
  • Generics Promotion in Japan
  • Ageing Population - A Prime Target
  • Competitive Landscape
  • Table 51: Leading Pharmaceutical Companies in Japan (2008): Percentage Breakdown of Revenues for Takeda Pharmaceuticals, Astellas Seiyaku, Dai-ichi Sankyo, Mitsubishi Tanabe, Chugai Seiyaku, Pfizer, Novartis, Eisai, GlaxoSmithKline and Otsuka Seiyaku (includes corresponding Graph/Chart)
  • Table 52: Leading Prescription Drugs in Japan (2006 and 2007): Value Sales in US$ Million for Blopress, Diovan, Norvasc, Lipitor, Aricept, Epogin, Takepron, Leuplin, Micardis and Amlodin (includes corresponding Graph/Chart)
  • Cancer Drugs to Witness Robust Growth
  • Biennial Price Reduction to Impact Markets of Key Therapeutic Classes
  • Product Launches
  • Strategic Corporate Developments
  • Select Key Players
• B. Market Analytics
  • Table 53: Japanese Recent Past, Current & Future Analysis for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)
  • Table 54: Japanese Historic Review for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart)

4. EUROPE

• A. Market Analysis
  • Current and Future Analysis
  • Pharmaceutical Spending on the Rise
  • Mounting Healthcare Bills Boost Generic Drugs Consumption
  • Biogenerics Foray into Europe
  • SNRIs Likely to Replace SSRIs
  • Research and Development
  • Table 55: European Investments in Pharma Research & Development: 2005-2007 (includes corresponding Graph/Chart)
  • Europe - The Research and Production Hub for Vaccines Worldwide
  • Parallel Trade in Europe
  • New Rules to Offer Respite to Parallel Traders
  • Manufacturers Seek Greater Control Over Supply Chain
  • Pharmaceutical Industry Overview In Select Countries
  • France
  • Germany
  • Generics
  • Exports
  • Production
  • Prices
  • New Molecular Entities
  • R&D Investments
  • Parallel trade
  • Genetically Manufactured Drugs
  • Table 56: German Genetically Manufactured Pharmaceuticals (2007): Percentage Breakdown of Sales by Type - Vaccines, Insulins, Interferons, Monoclonal Antibodies, Erythropoietin, and Others (includes corresponding Graph/Chart)
  • United Kingdom
  • Spain
  • Cost Containment Efforts
  • Increased Promotion for Generics
  • Re-launch of Reference Price System
  • Distribution
  • Italy
  • Generics Gain Traction
  • Sweden
  • Greece
  • Unique Pricing Model for Drugs
  • Product Launches
  • Strategic Corporate Developments
  • Select Key Players
• B. Market Analytics
  • Table 57: European Recent Past, Current & Future Analysis for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)
  • Table 58: European Historic Review for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

• A. Market Analysis
  • Current and Future Analysis
  • Overview of Pharmaceutical Industries in Select Countries
  • India
  • Competitive Advantage
  • Number of FDA Approved Plants in India Vis-a-Vis Other Countries
  • Increasing Disposable Income Driving Consumption of Drugs
  • Generics to Surge Growth in Exports
  • Manufacturers Continue to Target Developed Markets
  • India to Emerge as an Important Pharmaceutical Manufacturing Center
  • Threat from Other Asian Countries
  • India to Emerge as a Major Hub for Biogenerics
  • Acute Therapy Class Leads the Market
  • Table 59: Leading Therapeutic Categories in the Indian Pharmaceutical Industry- Percentage Share Breakdown of Value Sales for Anti-infectives, Gastrointestinal, Cardiovascular, Respiratory, Minerals and Vitamins, Analgesics, Women' s Health, Central Nervous System, Dermatology, and Others (includes corresponding Graph/Chart)
  • Increase in Private Healthcare Services
  • China
  • Chinese Pharma Industry Remains Immune to Global Crisis, for Now
  • Issues and Trends
  • Pharmaceutical Firms to Play Pivotal Role in Transforming Healthcare System
  • Brand Name Drugs to Exhibit Fastest Growth, While Generics Continue to Lead
  • Generics in China
  • Traditional Medicines - Substantial Share
  • Table 60: Leading Medicine Types in China (2005): Percentage share for Allopathic Medicines, Traditional Chinese Medicines (TCM), and Other Drugs (includes corresponding Graph/Chart)
  • Underserved Markets Prompt Government to Foster Development
  • Domestic EPO Market Booming, Domestic Players Continue their Domination
  • Chinese Antipsychotics Market to Witness Substantial Growth
  • Antidepressant Drugs to Exhibit Robust Sales
  • Indonesia
  • Market Features
  • Government-Enforced Pricing Control Over Essential Drugs
  • Distribution
  • Korea
  • Patent Expiries of Leading Drugs in South Korea: 2008 and 2009
  • Malaysia
  • Foreign Investments on the Rise
  • Domestic Market
  • Australia
  • Pharmaceutical Benefits Scheme
  • Government' s Industry Development Programs
  • Outlook
  • Product Launches
  • Strategic Corporate Developments
  • Select Key Players
• B. Market Analytics
  • Table 61: Asia-Pacific Recent Past, Current & Future Analysis for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)
  • Table 62: Asia-Pacific Historic Review for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart)

6. LATIN AMERICA

• A. Market Analysis
  • Current and Future Analysis
  • Strategic Corporate Developments
• B. Market Analytics
  • Table 63: Latin American Recent Past, Current & Future Analysis for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)
  • Table 64: Latin American Historic Review for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart)

7. REST OF WORLD

• A. Market Analysis
  • Current and Future Analysis
  • Product Launches
  • Strategic Corporate Developments
• B. Market Analytics
  • Table 65: Rest of World Recent Past, Current & Future Analysis for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)
  • Table 66: Rest of World Historic Review for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE